BioCryst Secures Major US Health Department Influenza Drug Deal

By Yahoo! Finance | Oct 1, 2024 at 07:30 AM EST

BioCryst Pharmaceuticals secured a $69 million contract with the U.S. Department of Health and Human Services to supply RAPIVAB® for influenza treatment over five years. The agreement aims to strengthen the Strategic National Stockpile for emergencies, with an initial order placed for 19,125 doses.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.